FOXA1 and cancer: By multivariate survival analysis, the non basal-like AR+ FOXA1+ CK14– subgroup was associated with longer cancer-specific survival (HR = 0.26, 95% CI: 0.07–0.89, p = 0.033) compared to the basal-like AR+ FOXA1– CK14+ subgroup (HR = 1.00) independently of the pathologic tumor size (pT ≥ 20 mm: HR = 2.15, 95% CI: 1.10–4.19, p = 0.026) and pathologic nodal stage (pN+: HR = 2.28, 95% CI: 1.17–4.46, p = 0.017) (Table 5).